Takeda Pharmaceutical Company Limited (TAK)

Trade TAK now with
11/17/2022 8:04:52 AM Takeda : Phase 3 Trial Of ICLUSIG Meets Primary Endpoint In Newly-Diagnosed Ph+ ALL
11/11/2022 2:17:00 AM Takeda: EC Grants Marketing Authorization For LIVTENCITYTM For Cytomegalovirus Infection
10/27/2022 2:31:57 AM Takeda Reports H1 Core Revenue Growth Of 5.5% At CER
10/20/2022 7:12:14 AM Takeda Enters Collaboration Deal With Zedira And Dr. Falk Pharma To Develop ZED1227/TAK-227
10/14/2022 7:34:21 AM Takeda Gets Positive CHMP Opinion Recommending Approval Of Dengue Vaccine Candidate In EU &Dengue-Endemic Countries
10/5/2022 8:19:37 AM FDA Accepts Takeda's SBLA For Use Of TAKHZYRO To Prevent Hereditary Angioedema Attacks In Children
9/20/2022 8:05:01 AM Canada Approves Takeda's LIVTENCITY For Treatment Of Adults With Post-transplant Cytomegalovirus Infection
9/16/2022 8:07:11 AM Takeda Gets Positive CHMP Opinion For Maribavir For Treatment Of Adults With Post-transplant CMV Refractory
9/14/2022 8:01:54 AM Takeda Announces National Launch Of CDPATH Program
9/7/2022 8:00:58 AM Takeda Canada Partners With The Canadian Institutes Of Health Research To Advance Research In Rare Diseases